NCT03356561View on ClinicalTrials.gov

A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

100

Participants

Timeline

Start Date

November 26, 2017

Primary Completion Date

September 23, 2019

Study Completion Date

September 23, 2019

Conditions

Healthy

Interventions

BIOLOGICAL

Ad26.ZIKV.001 5*10^10 vp

Participants will receive Ad26.ZIKV.001 at a dose of 5\*10\^10 vp via IM route.

BIOLOGICAL

Ad26.ZIKV.001 1*10^11 vp

Participants will receive Ad26.ZIKV.001 at a dose of 1\*10\^11 vp via IM route.

BIOLOGICAL

Placebo

Participants will receive placebo via IM route.

Trial Locations (2)

66219

Johnson County Clinical Trials, Lenexa

02215

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors

lead

Janssen Vaccines & Prevention B.V.

INDUSTRY

NCT03356561 - A Study to Evaluate the Safety, Reactogenicity and Immunogenicity of Ad26.ZIKV.001 in Healthy Adult Volunteers | Biotech Hunter | Biotech Hunter